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Abstract 

Objectives:  Presence of the apolipoprotein E (APOE) ũ4 allele is a risk factor for dementia, 
while the ũ2 allele offers protection against dementia. There is also evidence for a 
relationship between APOE genotype and changes in cognitive function. It is not clear 
however, whether this relationship stems from undetected disease in persons genetically more 
vulnerable to dementia. This study examined whether APOE genotype was associated with 
either initial performance or change in performance on a range of cognitive and non-
cognitive tasks, after accounting for possible preclinical dementia. 
Design:  A population-based cohort was assessed up to four times over 12 years. 
Participants: The sample was an Australian cohort of 590 participants aged 70 and over who 
were genotyped for APOE. 
Measurements: The outcomes were processing speed, verbal fluency, episodic memory, word 
recognition, face recognition, grip strength and reaction time. 
Results:  Adjusted latent growth models indicated that ũ4 carriers had significantly poorer 
initial memory performance and greater declines in processing speed and word recognition, 
compared to ũ2 and ũ3 carriers. In addition, ũ2 carriers exhibited significantly less decline in 
right grip strength than ũ3 carriers. However, after excluding 125 participants with low global 
cognition scores, all genotype effects became non-significant. 
Conclusions:  Over a 12 year period, findings indicate that APOE ũ4-related cognitive decline 
in older community-dwelling populations is due to a higher likelihood of preclinical dementia 
among ũ4 carriers. When possible dementia cases are removed from the analyses, ũ4 
associations with cognitive decline become statistically unreliable. 
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Introduction 
The apolipoprotein E (APOE) ũ4 allele is an established risk factor for dementia (e.g., 
1) while, conversely, the ũ2 allele offers protection against the disease (e.g., 2). Meta-
analyses also suggest both ũ4-related cognitive deficits, and ũ2-related cognitive benefits, in 
later life (3, 4). However, there is accumulating evidence that the subclinical phase of 
dementia precedes eventual diagnosis by several years, even decades. For instance, 
histopathological work (5, 6) suggests the neuropathological markers of the disease are 
present in middle-age and early adulthood, while cognitive deficits have been detected up to 
ten years before clinical diagnosis (7). A key question, therefore, is whether APOE genotype 
exerts a direct influence on cognition independently of dementia-related neuropathology as 
numerous studies suggest, or whether ũ4-related cognitive deficits represent a behavioral 
marker of the, as yet, undetected disease in persons genetically more vulnerable to earlier 
onset of dementia. It is this important question that motivates the present study.  
There is already evidence that the latter may be the case. For example, longitudinal 
studies suggest that when future dementia is taken in to account, APOE genotype-related 
variation in cognitive change is minimal (8, 9), and two recent large-scale studies suggest that 
the more marked cognitive decline observed in ũ4 carriers was probably associated with the 
presence of subclinical dementia-related neuropathology (10, 11).  
The present study builds upon this research and also extends the earlier work of Hofer 
et al. (12), who examined the effects of APOE on cognition in the present community-based 
population. Using the first three measurement points from the Canberra Longitudinal Study 
cohort (13), Hofer and colleagues examined the effects of APOE genotype on memory, 
processing speed and verbal ability, which were measured as latent constructs derived from 
multiple cognitive tasks. They found that the ũ4 allele was associated with poorer initial 
processing speed and greater declines in both speed and memory. In a cognitively intact 
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subsample, the effects on memory remained while the processing speed effects became non-
significant. However, the investigators were not able to control for possible neuropathology 
beyond the seven year assessment period of that study. The present analysis, therefore, used 
all four waves of the Canberra Longitudinal Study spanning 12 years, examined a broader 
range of cognitive measures that were not investigated in that earlier study individually, and 
adjusted for potential neuropathology over the entire 12-year period. We also investigated 
grip strength because decreased grip strength has been identified as a strong predictor of 
cognitive aging  (14, 15) and is associated with Alzheimer pathology and disease progression 
(16). 
Importantly, to test whether any effects of APOE on cognition were due to possible 
subclinical dementia pathology, we used broader exclusion criteria for possible dementia. 
Instead of using the Canberra Interview for the Elderly, a diagnostic instrument for dementia 
(17) used in the earlier study, a cut-off of 24 on the Mini-Mental State Examination (18) was 
used to exclude participants possibly in the preclinical dementia phase during the study 
period. Given evidence that the ũ2 allele may delay dementia onset and help preserve late-life 
cognitive performance (19), we additionally extended the earlier study (12) by examining the 
specific effects of the ũ2 allele on cognitive change. 
Following from the earlier work, we hypothesized that the APOE ũ4 allele would be 
associated with more precipitous decline in memory performance and processing speed. A 
non-specific protective effect of ũ2 on cognitive performance was also expected. However, 
APOE-related associations were expected to attenuate when possible dementia was taken into 
account. We also predicted that the ũ4 allele would be associated with weaker grip strength. 
More specifically, given evidence that dementia pathology has an earlier and more 
pronounced effect on the left cerebral hemisphere (20), and recent evidence that children with 
an ũ2 allele are more likely to be left handed (21), it was predicted that right-hand grip 
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strength, controlled by the left hemisphere, would exhibit greater decline in ũ4 carriers than 
non-carriers.  
 
Methods 
Participants 
The Canberra Longitudinal Study is an epidemiological survey of mental health and cognitive 
functioning in people aged 70 and over (13). Eight hundred and ninety-six participants (456 
men and 440 women) were recruited for the baseline assessment in 1990. All participants 
were initially living in the community in the cities of Canberra or Queanbeyan, Australia. 
Participants were sampled from the compulsory electoral roll, with 69% responding to a letter 
and/or phone call (see 22 for further description of the recruitment), and the sample was 
stratified by age and gender. Approval for the research was obtained from the Ethics in 
Human Experimentation Committee of The Australian National University and all 
participants provided written informed consent. 
The present sample (n = 590) comprised individuals successfully genotyped for 
APOE at Wave 2 of the study, excluding ten participants with genotype ũ2/4 and five 
participants whose genotype could not be established. We excluded persons with the ũ2/4 
genotype because the respective alleles exert opposing influences on cognition and dementia 
and, therefore, may cancel one another out. Of the 590 participants included in the analysis 
who completed Waves 1 and 2, 360 (61.0%) completed the Wave 3 assessment (152 
deceased, 78 dropouts) and 203 (34.4%) completed the Wave 4 assessment (295 deceased, 92 
dropouts).  Participants who completed the second interview have previously been reported to 
be younger, more educated, less disabled, have fewer diseases, have stronger grip strength, 
and have fewer depression symptoms than those who were not included in the analysis (23). 
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Survey Procedure 
Participants were interviewed up to four times over 12 years by trained professional 
interviewers. Baseline interviews lasted approximately two hours, and included a survey that 
covered background characteristics, physical health and disease status, mental health status, 
cognitive performance and social support. Interviews also included physical assessment of 
blood pressure, lung function, grip strength, vision and reaction time. 
 
APOE Genotype 
APOE genotyping was performed using DNA extracted from buccal swabs using a 
modification of the method of Richards et al. (24). Polymerase chain reaction amplification 
of a 234 base-pair fragment of exon 4 of the apoE gene followed by digestion with CfoI was 
used to determine APOE genotype. These were separated by polyacrylamide gel 
electrophoresis and displayed by silver staining. Of the 605 participants tested, APOE 
genotype was successfully determined for 600. After excluding the 10 participants who had 
an ũ2/4 genotype, the sample (n = 590) consisted of 11.0% having an ũ2 gene (n = 2 with 
ũ2/2; n = 63 with ũ2/3), 23.2% having an ũ4 gene (n = 127 with ũ3/4; n = 10 with ũ4/4) and 
the remaining 65.8% being homozygous for ũ3 (n = 388). 
  
Measures 
A range of cognitive tests was administered at each interview. Speed of processing was 
measured by the Symbol-Letter Modalities Test (SLMT), a task similar to Smith’s (25) 
Symbol-Digit Modalities Test and Wechsler’s (26) Digit-Symbol Substitution. The number 
of correct symbol-letter pairs made in 90 seconds was summed. Verbal fluency was assessed 
as the number of animals named in 30 seconds [adapted from (27) to reduce participant 
burden]. An episodic memory task consisted of four brief episodic memory tasks testing 
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word, face, name and address  recall and figure reproduction (28). Face and word recognition 
tasks were based on the Rivermead Behavioural Memory Test (29). To facilitate comparisons 
between tests, all of the cognitive and grip strength measures were standardized to a common 
metric, with a mean of 100 and standard deviation of 10 for the complete baseline sample. 
To measure choice reaction time, participants were asked to press a button with their 
left or right hand depending on which of two stimulus lights were illuminated (interstimulus 
intervals ranged from 0.5 to 2.0 seconds) (30), and choice reaction time was measured as the 
mean response time over 20 trials. Grip strength was taken using a Smedley hand 
dynamometer which measures the force exerted in kilograms (30). Measurements were taken 
for both right and left hands. 
The Mini-Mental State Examination (MMSE: 18), scored out of 30, was used to 
screen for possible preclinical dementia. Following consideration of the broader literature 
(31, 32), participants with MMSE scores ≤ 24 at any assessment were excluded to assess 
whether any effects of APOE on cognitive performance were attributable to possible 
dementia. Norms for the MMSE indicate sensitivity of 95% and specificity of 82% for 
detecting Alzheimer’s Disease at this cut point in community-based individuals who are 80 
years or older with nine or more years of education (most participants in the present study 
were in this category by the second wave) (33).  
Additional control variables included in each model were age, gender and years of 
education. Years of education were assessed using a single self-report item. 
 
Analysis 
Latent growth models estimating the level (intercept) and slope of performance on 
each of the eight outcome measures were run. Latent growth models are a class of structural 
equation models that represent individual level data in terms of an initial level of performance 
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latent variable or factor (level), a rate of change factor (slope), and error (residual) parameters 
(12, 34). These structures are analogous to random intercept and slope terms in mixed 
models. However, latent growth modeling uses a multivariate approach, such that an outcome 
variable measured at four occasions gives rise to a four-variate outcome vector (35). Like 
mixed models, latent growth models accommodate missing data, appropriately accommodate 
unequal numbers of individual observations, account for dependencies among observations 
within individuals, and account for individual differences in the rates of cognitive decline 
(36).  
Separate models were used to assess the role of APOE genotype on each of the 
outcome variables. In order to delineate and maximize allelic influence while retaining 
statistical power, the genotype combinations used in the models were as follows: ũ2 = ũ2/2+ 
ũ2/3; ũ3 = ũ3/3; ũ4 = ũ3/4+ũ4/4. To assess all possible genotype comparisons, the models 
were run using ũ3 as the reference category, then repeated with ũ2 as the reference category. 
These models were each estimated twice: once with all participants and once excluding 
participants with possible preclinical dementia (MMSE ≤ 24 at any assessment). Mplus 
version 6 was used to estimate the latent growth models which incorporated all available data 
under the missing at random assumption. To illustrate the effects found in the models, mixed 
model repeated measures analyses of variance were used to estimate cognitive performance 
over time, adjusting for age, gender, education and genotype. Finally, a logistic regression 
analysis was used to examine baseline predictors of having MMSE ≤ 24 at any time point. 
PASW version 18 was used to estimate both the mixed effects models and logistic regression 
model. 
 
Results 
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Individuals in the analysis sample were an average age of 76.2 years at the first 
assessment (SD = 4.7, range = 70-93 years), and had mean 11.5 years of education (SD = 
2.6). Due to the gender stratification, the sample was 49.0% men and 51.0% women. The 
analysis sample was significantly younger (76.2 vs. 77.2 years; F1,894 = 9.29, p = 0.002) and 
better educated (11.5 vs. 11.0 years; F1,892 = 7.45, p = 0.006) than the full sample, but did not 
differ in gender distribution (21 = 2.52, p = 0.112). Descriptive statistics for the analysis 
sample are shown in Table 1, both overall and by APOE genotype group. As indicated in the 
table, there were no differences across genotype groups as assessed at the initial assessment, 
with the exception of word recognition where 4 carriers performed significantly worse than 
2 and 3 carriers. There was also some indication of poorer performance on episodic 
memory and MMSE in 4 carriers compared to 2 and 3 carriers, although the differences 
were not significant (p = 0.07). Mixed effects models indicated that performance on all of the 
outcomes declined significantly over time. Adjusted for age, gender, education and APOE, 
the effect of time was significant at p< 0.001 for all outcomes (F3, 202-370 range: 11.1 – 226.2). 
In Table 2, the latent growth model shows that the rate of decline in processing speed 
(SLMT) was significantly greater for ũ4 relative to both ũ3 (p = 0.002) and ũ2 (p = 0.048) 
carriers. The initial level of episodic memory performance was significantly lower for ũ4 
allele than for ũ2 (p = 0.015). The level of word recognition performance was significantly 
lower for ũ4 than for both ũ3 (p = 0.031) and ũ2 (p = 0.007), while there was significantly 
greater decline in word recognition performance among ũ4 carriers compared to ũ3 (p = 
0.006). Initial face recognition performance was significantly poorer for ũ4 than ũ2 (p = 
0.028). Right hand grip strength declined significantly less in ũ2 participants relative to ũ3 (p 
= 0.031).  
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The effect of genotype on cognition is illustrated in Figure 1, which shows word 
recognition performance for participants 70-79 and  80 across the four time points. Values 
in the figure are based on estimated marginal means from a mixed model repeated measures 
ANOVA adjusted for age group, gender, education and genotype. The effect of ũ4 is evident 
in terms of both the poorer performance at baseline (particularly among the 70-79 group) and 
the greater decline in performance of both ũ4 groups over the four waves. 
 Importantly however, after excluding participants (n = 125) with possible preclinical 
dementia (i.e., persons with MMSE score ≤ 24 at any time point), the estimated genotype 
effects were greatly attenuated such that none of the original effects remained significant 
(Table 3). Participants who met this criterion performed significantly more poorly on all of 
the cognitive tests administered at the second assessment, scoring one SD lower on SLMT, 
word recognition, face recognition and episodic memory (t 559-570 = 8.04-11.33, p < 0.001 for 
all), suggesting some indication of cognitive deficit. The genotype distribution in this analysis 
was significantly different to the analysis without the exclusion. Notably, a greater proportion 
of ũ4 carriers had low MMSE scores (ũ2: n = 56 included/14% excluded, ũ3: n = 313 
included/19% excluded, ũ4: n = 96 included/30% excluded; 2 = 9.2, p = 0.01). Nevertheless, 
the analysis had sufficient power to detect small differences between the ũ3 and ũ4 groups 
(conservatively assuming n = 96 per group, the power to detect an effect size of 0.2 between 
group effects was 0.93). The attenuation is illustrated in Figure 2 which shows the word 
recognition effect for those participants who did not have MMSE ≤24 at any time point. The 
values in this figure were estimated in the same way as those in Figure 1. The attenuation of 
the APOE effect can be seen in the overlap between the six groups. Also of note is that the 
slopes of all groups in Figure 2 appear to be relatively flat, suggesting much of the 
performance decline in the initial analyses was due to possible preclinical dementia as 
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opposed to age-based effects. Note that no participants with the ũ4 genotype in the 80s group 
remained by the fourth wave after excluding for MMSE ≤ 24, a result specific to the present 
cohort. 
 To investigate possible mediators of the relationship between ũ4 and low MMSE 
scores, baseline predictors of having MMSE ≤ 24 at any time point were examined in a 
logistic regression model. The model simultaneously included the effects of age, gender, 
years of education, marital status (married, single, widowed, divorced/separated), depression 
and anxiety symptoms (37), disease count (from a list of 14 conditions), physical functioning 
(38) and smoking status (never, past, current), all reported at the baseline assessment. Only 
increased age [OR = 1.07, 2 (1) = 12.0, p = 0.001], fewer years of education [OR = 0.86, 2 
(1) = 15.5, p = 0.001] and being widowed or divorced/separated were significantly associated 
with low MMSE scores [marital status omnibus 2 (3) = 9.1, p = 0.028; widowed vs. married: 
OR = 1.69, 2 (1) = 5.9, p = 0.016; divorced/separated vs. married: OR = 2.39, 2 (1) = 5.0, p 
= 0.026], reflecting previously reported associations (39). 
 
Discussion 
This study possesses several important features. First, we assessed cognitive change in 
old age across a range of cognitive and non-cognitive variables as a function of APOE 
genotype over a 12 year period. To our knowledge, there are no other longitudinal studies of 
APOE and cognitive change over this length of time in older community-based populations 
that have controlled for possible dementia. Second, we carefully delineated between APOE 
genotype in order to assess the primary effects of the ũ2 allele (protective effect) relative to 
the ũ3 allele (neutral) and, in turn, the ũ4 allele (high vulnerability), in relation to cognitive 
decline. Additionally, in a repeat analysis, we removed persons considered high-risk for 
subclinical dementia. There were several important findings arising from the study. First, 
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persons possessing the ũ4 allele exhibited lower initial scores in episodic memory, word 
recognition and face recognition than non-ũ4 carriers. 4 carriers also showed more marked 
decline over time in processing speed and word recognition. Second, although the protective 
effect of the ũ2 allele was not demonstrated in relation to the cognitive variables, ũ2 carriers 
declined less in right-hand grip strength than ũ3 carriers. Importantly however, when persons 
with possible dementia neuropathology were removed from the sample, all of these APOE-
related effects became non-significant.  
The findings build upon earlier work on this dataset (12) by extending the analysis 
period to 12 years, examining a broader range of cognitive and non-cognitive variables, and 
using broader exclusion criteria for possible dementia. The findings have some important 
implications. First, they suggest that ũ4-related cognitive decline in old age is associated with 
the preclinical phase of, as yet, undetected dementia rather than an independent effect of 
APOE genotype on cognition. Although we did not formally assess clinical dementia, when 
persons with low MMSE scores were removed from the sample, APOE-related effects 
disappeared. As low MMSE scores are associated with a higher likelihood of dementia (31, 
32), this finding is consistent with several other studies (e.g., 8, 9, 10) that demonstrate null 
ũ4-related effects when future dementia is controlled for. Given accumulating evidence that 
the subclinical phase of the disease extends years, and perhaps decades, ahead of the eventual 
clinical manifestations, the findings support the view that both APOE genotype and 
neuropsychological assessment could be taken into account in procedures for the early 
detection of dementia. 
It also appears that the protective effect of the ũ2 allele may reflect the hemispheric 
specificity of incipient neuropathology. As we expected, an APOE effect was detected for 
grip strength in the right hand. This prediction was made because it is now well documented 
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that brain aging and dementia-related pathology affect the left hemisphere earlier and more 
strongly than the right (20). Since the left hemisphere controls the right hand, deficits in grip 
strength would be expected first in the right hand. While we detected a protective effect for 
the ũ2 relative to the ũ3 allele for right hand grip strength, what is surprising is that we did 
not find an association between weaker grip strength and the ũ4 allele. This suggests a 
protective effect of the ũ2 allele against neuropathology, particularly since this disappeared in 
analyses that excluded persons with low MMSE scores.  
A major concern in any study where significant effects disappear when participants are 
removed from the analyses is that reducing sample size affected statistical power. In the 
present context, this raises the question of whether our null results in the repeated analyses 
simply reflect a Type II error. We are confident that this was not the case, as a conservative 
post hoc power analysis found 93% power to detect an effect size of 0.2 between the ũ3 and 
ũ4 carriers. However, it is important to note that in our repeat analyses significantly more ũ4 
carriers were removed from the sample due to low MMSE scores. As ũ4 carriers are 
genetically more vulnerable to earlier onset of dementia, this finding is consistent with the 
possibility that those excluded persons were more likely to be in the subclinical phase of the 
disease. 
The study does possess several limitations that we should acknowledge. First, although 
we removed persons with low MMSE scores due to the higher likelihood that they may be 
experiencing dementia-related neuropathology, we were unable to confirm diagnosis. 
However, the MMSE criterion used in the present study drew upon work elsewhere (31, 32), 
and was broader in excluding possible dementia cases than the Canberra Interview for the 
Elderly criteria which in the earlier study detected only 30 dementia cases at any time point 
(compared to n = 125 with MMSE ≤24 here). Although the MMSE is not a conclusive 
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screening tool for dementia, we believe our approach represents a reasonable method of 
excluding possible dementia cases, given the constraints of available data. The present 
findings would be strengthened if replicated in other samples using mediation analyses with 
clinical measures assessing preclinical dementia. Second, as is unfortunately inevitable in 
studies of this age group, there was a high level of mortality by Wave 4. Although we still 
retained a reasonable sample size compared to other late-life cohort studies, our findings 
accordingly should be treated with appropriate caution. Third, although our 
neuropsychological battery assessed a comprehensive range of cognitive domains including 
executive function and episodic memory, both shown to be sensitive to ũ4-related effects (3, 
4), it remains possible that our battery was insufficiently broad to capture the effects of 
interest. Future work from our laboratories will address this issue using other datasets. 
Fourth, the available data were not sufficient for investigating quadratic or exponential 
changes in cognition (across four waves) and did not provide sufficient numbers of e2/2 and 
e4/4 homozygotes to separate homozygotes from heterozygotes. Finally, APOE genotyping 
took place at Wave 2 of the study, and therefore excluded those who died or withdrew after 
baseline assessment. This may have led to a genetically more homogeneous sample resulting 
in more conservative estimates. 
To conclude, this study adds to evidence that APOE ũ4-related cognitive decline in 
older community-dwelling populations is due to a higher likelihood of, as yet, undetected 
dementia among ũ4 carriers. Moreover, the findings also suggest a protective effect for 
persons in possession of the ũ2 allele. It is important that further longitudinal work is 
undertaken in community-based populations to confirm these findings. If the more 
precipitous cognitive decline commonly reported among older ũ4 carriers is due to a greater 
proportion of those persons eventually becoming demented, it suggests that both 
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neuropsychological testing and APOE genotyping could inform early detection programs for 
dementia in early old age.  
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Table 1: Descriptive statistics at the initial interview for participants included in the analysis, both overall and by genotype 
 
 
Total  
(n = 590)  
APOE e2 group  
(n = 65)  
APOE e3 group  
(n = 388)  
APOE e4 group  
(n = 137)  
Comparison of 
APOE groups 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
F p 
Age 76.19 4.70 
 
76.17 4.22 
 
76.38 4.75 
 
75.68 4.75 
 
1.126 0.325 
Years of education 11.52 2.64 
 
11.23 2.52 
 
11.57 2.66 
 
11.52 2.64 
 
0.436 0.647 
Disease count 2.72 1.65 
 
2.58 1.59 
 
2.81 1.67 
 
2.53 1.60 
 
1.777 0.170 
Goldberg depression 1.85 1.83 
 
2.03 2.02 
 
1.89 1.85 
 
1.66 1.67 
 
1.145 0.319 
Goldberg anxiety 2.41 2.22 
 
2.44 2.50 
 
2.32 2.17 
 
2.63 2.22 
 
0.996 0.370 
Activities of daily living score 1.56 2.03 
 
2.05 2.40 
 
1.49 1.98 
 
1.54 1.96 
 
2.139 0.119 
Symbol-Letter Modalities  99.31 15.01 
 
100.42 15.50 
 
99.71 15.13 
 
97.69 14.42 
 
1.102 0.333 
Verbal fluency 11.26 3.39 
 
11.46 3.05 
 
11.22 3.45 
 
11.28 3.39 
 
0.142 0.868 
Episodic memory 13.65 1.94 
 
14.06 1.56 
 
13.66 2.05 
 
13.39 1.73 
 
2.689 0.069 
Word recognition 0.96 0.07 
 
0.97 0.06 
 
0.96 0.07 
 
0.94 0.09 
 
4.477 0.012 
Face recognition 0.79 0.09 
 
0.80 0.08 
 
0.79 0.10 
 
0.78 0.10 
 
1.259 0.285 
Choice reaction time 471.52 140.38 
 
467.69 121.34 
 
475.11 140.93 
 
463.19 147.73 
 
0.360 0.698 
Right grip strength 26.39 10.30 
 
24.88 9.29 
 
26.31 10.18 
 
27.34 11.04 
 
1.277 0.280 
Left grip strength 24.15 9.80 
 
23.65 9.45 
 
24.03 9.75 
 
24.76 10.13 
 
0.378 0.685 
Mini-Mental State Exam 27.85 1.98 
 
27.96 1.65 
 
27.96 1.96 
 
27.52 2.15 
 
2.612 0.074 
APOE and cognitive decline in late life    22 
 
 
Total  
(n = 590)  
APOE e2 group  
(n = 65)  
APOE e3 group  
(n = 388)  
APOE e4 group  
(n = 137)  
Comparison of 
APOE groups 
 
Count % 
 
Count % 
 
Count % 
 
Count % 
 

2
 p 
Female gender 301 51.0% 
 
36 55.4% 
 
197 50.8% 
 
68 49.6% 
 
0.610 0.737 
Current smoker 254 43.1% 
 
24 36.9% 
 
172 44.3% 
 
58 42.3% 
 
4.675 0.322 
Marital status 
              
Married 337 57.1% 
 
39 60.0% 
 
217 55.9% 
 
81 59.1% 
 
2.585 0.859 
Widowed 208 35.3% 
 
22 33.8% 
 
143 36.9% 
 
43 31.4% 
   
Divorced/separated 21 3.6% 
 
2 3.1% 
 
12 3.1% 
 
7 5.1% 
   
Single 24 4.1% 
 
2 3.1% 
 
16 4.1% 
 
6 4.4% 
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Table 2:  Latent growth curve models of cognitive performance, reaction time and grip 
strength, adjusted for gender, initial age and education (n ≤ 590) 
 
    APOE 2 vs. 3 APOE 4 vs. 3 APOE 4 vs. 2 
    Estimate p Estimate p Estimate p 
SLMT intercept 0.567 0.590 -1.146 0.137 -1.713 0.146 
slope -0.047 0.920 -1.110 0.002 -1.063 0.048 
Verbal fluency intercept -0.436 0.726 0.214 0.814 0.650 0.641 
slope 0.889 0.161 -0.449 0.357 -1.338 0.066 
Episodic memory intercept 1.457 0.142 -1.265 0.085 -2.721 0.015 
slope 0.250 0.701 -0.239 0.635 -0.489 0.512 
Word recognition intercept 1.492 0.144 -1.626 0.031 -3.118 0.007 
slope -0.205 0.805 -1.768 0.006 -1.564 0.098 
Face recognition intercept 1.220 0.248 -1.377 0.074 -2.597 0.028 
slope -1.040 0.104 -0.924 0.060 0.117 0.873 
Choice RT intercept -1.231 0.146 0.017 0.978 1.249 0.189 
slope 0.133 0.844 -0.314 0.543 -0.447 0.562 
Right grip intercept -0.573 0.508 0.415 0.518 0.989 0.310 
slope 0.765 0.031 0.138 0.622 -0.627 0.125 
Left grip intercept 0.247 0.753 0.029 0.961 -0.218 0.805 
slope 0.184 0.576 0.055 0.831 -0.129 0.734 
 
Notes:  Bold values indicate p < 0.05; APOE 2: apolipoprotein E genotypes 22/23; APOE 3: 
apolipoprotein E genotype 33; APOE 4: apolipoprotein E genotypes 34/44; SLMT: Symbol-
Letter Modalities Test; Choice RT: choice reaction time 
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Table 3:  Latent growth curve models excluding participants with MMSE ≤ 24 at any time 
point, adjusted for gender, initial age and education (n ≤ 465) 
 
    APOE 2 vs. 3 APOE 4 vs. 3 APOE 4 vs. 2 
    Estimate p Estimate p Estimate p 
SLMT intercept 0.911 0.403 0.179 0.836 -0.732 0.561 
slope -0.576 0.190 -0.595 0.095 -0.018 0.972 
Verbal fluency intercept 0.049 0.971 -0.054 0.959 -0.103 0.947 
slope 0.442 0.503 -0.242 0.653 -0.684 0.381 
Episodic memory intercept 1.426 0.095 -0.367 0.589 -1.793 0.070 
slope -0.110 0.845 -0.017 0.971 0.093 0.888 
Word recognition intercept 0.956 0.194 -0.700 0.232 -1.656 0.052 
slope 0.186 0.765 0.276 0.595 0.090 0.902 
Face recognition intercept 0.432 0.681 -0.397 0.630 -0.829 0.494 
slope -0.555 0.355 -0.455 0.349 0.100 0.887 
Choice RT intercept -1.334 0.099 0.034 0.958 1.368 0.144 
slope 0.102 0.866 -0.237 0.629 -0.339 0.632 
Right grip intercept -0.032 0.972 0.541 0.457 0.573 0.586 
slope 0.603 0.100 0.247 0.427 -0.356 0.415 
Left grip intercept 0.497 0.551 -0.077 0.909 -0.574 0.554 
slope 0.122 0.725 0.247 0.397 0.125 0.760 
 
 Notes:  Bold values indicate p < 0.05; APOE 2: apolipoprotein E genotypes 22/23; APOE 3: 
apolipoprotein E genotype 33; APOE 4: apolipoprotein E genotypes 34/44; SLMT: Symbol-
Letter Modalities Test; Choice RT: choice reaction time 
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Figure 1:  Effect of APOE genotype and age group on word recognition performance across 
the four time points 
 
Notes: Values are estimates from mixed model repeated measures ANOVA; error bars 
represent standard errors;  APOE:  apolipoprotein E; Scores were standardized at baseline 
to M =100 and SD = 10 
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Figure 2:  Effect of APOE genotype and age group on word recognition performance across 
the four time points, excluding participants with MMSE ≤ 24 at any time point 
 
 
Notes: Values are estimates from mixed model repeated measures ANOVA; error bars 
represent standard errors;  APOE = apolipoprotein E; Scores were standardized at baseline 
to M =100 and SD = 10 
 
 
